• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Nuvalent Inc.

    9/29/25 4:07:27 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NUVL alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001862147
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Nuvalent, Inc.
    SEC File Number
    001-40671
    Address of Issuer
    One Broadway, 14th floor
    Cambridge
    MASSACHUSETTS
    02142
    Phone
    8573577000
    Name of Person for Whose Account the Securities are To Be Sold
    Alexandra Balcom
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Class A Common
    J.P. Morgan Securities LLC
    390 Madison Avenue
    6th Floor
    New York � NY � 10017
    6000048780006666958309/29/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Class A Common09/29/2025Stock Option ExerciseIssuerCheckbox not checked6000009/29/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Alexandra Balcom
    One Broadway, 14th Floor
    Cambridge � MA � 02142
    Class A Common07/15/20255300442521
    Alexandra Balcom
    One Broadway, 14th Floor
    Cambridge � MA � 02142
    Class A Common07/16/2025147001250952

    144: Remarks and Signature

    Remarks
    The sales under this filing are from Cashless Option Exercises that will occur within 3 months from the date of this filing.
    Date of Notice
    09/29/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    12/12/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Alexandra Balcom

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $NUVL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUVL

    DatePrice TargetRatingAnalyst
    11/24/2025Buy
    Truist
    11/12/2025$126.00Buy
    Canaccord Genuity
    10/16/2025$115.00Buy
    Stifel
    10/15/2025$135.00Overweight
    Cantor Fitzgerald
    9/4/2025$122.00Buy
    Guggenheim
    9/3/2025$105.00Outperform
    Raymond James
    8/19/2025$112.00Overweight
    Piper Sandler
    3/14/2025$100.00Neutral → Buy
    UBS
    More analyst ratings

    $NUVL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuvalent Appoints Ron Squarer to Board of Directors

    CAMBRIDGE, Mass., Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Ron Squarer to its Board of Directors. "We welcome Ron to our Board of Directors, where his personal dedication to advancing oncology therapeutics, demonstrated success in evolving research and development organizations to fully integrated businesses, and proven global commercial acumen will strengthen and sharpen our pre-launch

    12/10/25 4:01:00 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference

    CAMBRIDGE, Mass., Nov. 26, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025, at 8:30 a.m. ET. A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and

    11/26/25 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders

    CAMBRIDGE, Mass., Nov. 24, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its previously announced underwritten public offering of 4,950,496 shares of Class A common stock at a price to the public of $101.00 per share. The offering closed on November 20, 2025. The gross proceeds to Nuvalent from the offering were approximately $500.0 million, before deducting underwriting discounts and commissions and other offering expenses.

    11/24/25 4:01:00 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    SEC Filings

    View All

    SEC Form 8-K filed by Nuvalent Inc.

    8-K - Nuvalent, Inc. (0001861560) (Filer)

    12/10/25 4:05:41 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Nuvalent Inc.

    8-K - Nuvalent, Inc. (0001861560) (Filer)

    11/20/25 6:01:19 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Nuvalent Inc.

    424B5 - Nuvalent, Inc. (0001861560) (Filer)

    11/19/25 4:53:27 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Squarer Ron was granted 2,837 shares (SEC Form 4)

    4 - Nuvalent, Inc. (0001861560) (Issuer)

    12/11/25 4:31:14 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Squarer Ron

    3 - Nuvalent, Inc. (0001861560) (Issuer)

    12/11/25 4:30:38 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Balcom Alexandra sold $781,537 worth of shares (7,084 units at $110.32), decreasing direct ownership by 11% to 54,650 units (SEC Form 4)

    4 - Nuvalent, Inc. (0001861560) (Issuer)

    12/10/25 4:30:35 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Nuvalent

    Truist initiated coverage of Nuvalent with a rating of Buy

    11/24/25 8:30:57 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Nuvalent with a new price target

    Canaccord Genuity initiated coverage of Nuvalent with a rating of Buy and set a new price target of $126.00

    11/12/25 8:57:08 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel resumed coverage on Nuvalent with a new price target

    Stifel resumed coverage of Nuvalent with a rating of Buy and set a new price target of $115.00

    10/16/25 8:51:17 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Leadership Updates

    Live Leadership Updates

    View All

    Nuvalent Appoints Ron Squarer to Board of Directors

    CAMBRIDGE, Mass., Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Ron Squarer to its Board of Directors. "We welcome Ron to our Board of Directors, where his personal dedication to advancing oncology therapeutics, demonstrated success in evolving research and development organizations to fully integrated businesses, and proven global commercial acumen will strengthen and sharpen our pre-launch

    12/10/25 4:01:00 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

    Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of 2025 Initiated ALKAZAR Phase 3 randomized, controlled trial of neladalkib for front-line ALK-positive NSCLC Topline pivotal data for neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC expected by year-end 2025 Preliminary data for neladalkib in patients with ALK-positive solid tumors beyond NSCLC to be presented at the ESMO Congress 2025 Jason Waters, MBA, promoted to Senior Vice President, Commercial CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical

    8/7/25 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Appoints Christy Oliger to Board of Directors

    CAMBRIDGE, Mass., June 18, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Christy Oliger to its Board of Directors. "Christy's proven success in delivering new therapies to patients living with cancer strengthens our Board as we evolve from a development-stage company toward potential commercialization," said James Porter, Ph.D., Chief Executive Officer at Nuvalent. "We welcome her deep expertise and

    6/18/25 4:30:00 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Financials

    Live finance-specific insights

    View All

    Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC

    In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month landmarks, respectivelyIn the subset of 63 TKI pre-treated patients who were lorlatinib-naïve, ORR by BICR was 46% (95% CI: 33, 59), with initial estimated durability of response of 80% and 60% at the 12- and 18-month landmarks, respectivelyNeladalkib demonstrated intracranial responses, ability to address key drivers of disease progression, and a generally well-tolerated safety profile with low rates of dose discontinuation (5%) and dose reduction (17%) due to TEAEs, consistent with its ALK-selective, TRK-sparing designCompany p

    11/17/25 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib

    Company to host webcast and conference call on November 17, 2025 at 8:00am ET CAMBRIDGE, Mass., Nov. 14, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the company will host a webcast and conference call on Monday, November 17, 2025 at 8:00 a.m. ET, to discuss topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 Phase 1/2 clinical trial.

    11/14/25 4:01:00 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

    Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the company plans to initiate a rolling NDA submission in July 2025 with target completion in the third quarter of 2025In 117 ROS1 TKI pre-treated patients, including 50% who had received ≥ 2 prior ROS1 TKIs ± chemotherapy, ORR by BICR was 44% (95% CI: 34, 53) with initial estimated durability of response of 78% at the 12-month landmark and 62% at the 18-month landmarkIn the subset of 55 patients treated with 1 prior ROS1 TKI (crizotinib or entrectinib) ± chemotherapy, ORR was 51% (95% CI: 37, 65) with initial estimated durability of respo

    6/24/25 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nuvalent Inc.

    SC 13G/A - Nuvalent, Inc. (0001861560) (Subject)

    11/14/24 4:50:28 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nuvalent Inc.

    SC 13G/A - Nuvalent, Inc. (0001861560) (Subject)

    11/14/24 4:34:36 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nuvalent Inc. (Amendment)

    SC 13G/A - Nuvalent, Inc. (0001861560) (Subject)

    5/15/24 6:39:30 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care